Xience pro

All interventions were performed using standard techniques. Predilation, postdilation, and use of intracoronary imaging (intravascular ultrasound (IVUS) or optical coherence tomography (OCT)) were left to the operator's discretion, as well as the decision to implant a further stent in patients with ESV-confirmed SF. ESV system utilization was mandatory after stent implantation and after postdilation (if it was performed). The following DES were implanted: Xience V or Xience Prime or Xience PRO (Abbott Vascular, Santa Clara, CA, USA), Promus Element or Promus Premier (Boston Scientific, Natick, MA, USA), Biomatrix Flex (Biosensors Europe SA, Morges, Switzerland), and Cre8 (CID and Alvimedica. S.P.A., Saluggia, Italy). After the procedure, all patients were advised to continue dual antiplatelet therapy (DAPT) with aspirin and P2Y12 inhibitor months after 2nd-generation DES implantation in patients with SF-predisposing factors. Secondary endpoints were: (1) any component of the primary endpoint; (2) definite and probable stent thrombosis (ST), and (3) target vessel revascularization (TVR). Finally, as a preliminary analysis, we compared the occurrence of the primary endpoint in patients with SF III-IV stratified according to the implantation (or not) of a further stent. All endpoints were adjudicated by an independent reviewer (R.P.), who was unaware of any data.